High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumes.

Publication Type:

Journal Article


Journal of nuclear medicine : official publication, Society of Nuclear Medicine, Volume 45, Issue 6, p.1059-64 (2004)


Adult, Aged, Antibodies, Monoclonal, Body Burden, Dose-Response Relationship, Radiation, Female, Humans, Kidney, liver, lung, Lymphoma, Non-Hodgkin, Male, Middle Aged, Organ Size, Organ Specificity, Radioimmunotherapy, Radiometry, Radiopharmaceuticals, Radiotherapy Dosage, Radiotherapy Planning, Computer-Assisted, Relative Biological Effectiveness, Spleen, TISSUE DISTRIBUTION


Radioimmunotherapy (RIT) using (131)I-tositumomab has been used successfully to treat relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). Our approach to treatment planning has been to determine limits on radiation absorbed dose to critical nonhematopoietic organs. This study demonstrates the feasibility of using CT to adjust for actual organ volumes in calculating organ-specific absorbed dose estimates.